商业与复合制剂在儿科眼科医学的对比
Annegret Dahlmann-Noor1,2,3, Jill Bloom4, Saw Keng Lee4
1University College London, Institute of Ophthalmology, 11-43 Bath Street, London, EC1V 9EL, UK. Anngret.dahlmann@ucl.ac.uk.
Paediatric drugs
|June 27, 2024
概括
由于罕见疾病,儿科眼科经常使用非标签或复合药物. 现在,商业制剂,如用于近视管理的低度氨酸等,在对儿童进行严格的临床试验后开始可用.
科学领域:
- 眼科医生 眼科 眼科
- 儿科医学 儿科医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿科眼科医生经常管理罕见疾病,导致非标签处方的药物没有专门测试在儿童身上.
- 罕见病患者人数有限往往阻碍了商业药物生产,导致人们依赖具有可变质量保证的复合制剂.
- 从历史上看,由于缺乏商业上可用的,经过儿童测试的治疗方法,复合药物一直很普遍.
研究的目的:
- 为儿童眼科中使用的复合制剂和商业制剂提供概述.
- 为突出儿童眼部疾病评估的药物选择的可用性最近的发展.
- 讨论商业准备的出现,以近视治疗为例.
主要方法:
- 关于药物使用的儿科眼科现行实践的审查.
- 分析从复合制剂过渡到商业制剂的情况.
- 检查最近的临床试验数据,以告知新进入市场的数据,例如近视症的低度氨酸.
主要成果:
- 在儿科临床试验中经过严格评估的商业制剂越来越多地用于特定的适应症.
- 近视管理是一个关键的领域,正在引入市场准备的,基于证据的治疗方法.
- 最近的国际临床试验支持的低度氨酸配方现在正在进入市场.
结论:
- 儿科眼科药物治疗的景观正在演变,转向评估的商业制剂.
- 与复合替代品相比,这种趋势提供了更好的质量保证和治疗标准化.
- 基于证据的商业选择的可用性,如近视控制,代表了儿童眼科护理的重大进展.
相关概念视频
01:16Bioequivalence: Overview
983
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
983
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
184
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
184
01:12Two-Compartment Open Model: Extravascular Administration
176
The two-compartment model for extravascular administration represents a drug's absorption and distribution process. It features a central compartment, where the drug is first absorbed, and a peripheral compartment, which illustrates the drug's distribution throughout the body. The rate of change in drug concentration in the central compartment is calculated by three exponents: absorption, distribution, and elimination.
The absorption exponent (ka) indicates the speed at which the drug...
The absorption exponent (ka) indicates the speed at which the drug...
176
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
961
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
961